ClinicalTrials.gg
RecruitingNCT07681466CHRONOpSUpdated Jul 2, 2026

Chronology and Sequence of Premonitory Symptoms

An observational study in Migraine, sponsored by University of Roma La Sapienza. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by University of Roma La Sapienza · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Migraine Disorders with a site in Italy — 37 open to participants now, 47 under way, 13 of them phase 3. Migraine Disorders · Italy.

Planned enrollment
8th of 42
500 · median 108
Started
2026
with 1 other
Observational
42 of 115
26 open now
Primary completion
2027-03
later than 29 of 46 live
Registered
114th of 115
by date
Lead sponsor
6 of 115
University of Roma La Sapienza

Among the 115 studies in Migraine Disorders with a site in Italy, this one is the 8th largest by planned enrollment of the 42 observational ones that give a count, is one of 2 that started in 2026, is one of 42 observational ones, reaches primary completion later than 29 of the 46 other live ones, and was the 114th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

37 of the 115 studies in Migraine Disorders with a site in Italy are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Migraine Disorders with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to prospectively investigate the temporal sequence of premonitory symptoms across multiple migraine attacks.

Read the detailed description

The premonitory phase marks the transition from the interictal to the headache phase and is considered the beginning of the migraine attack. During this phase, changes in brain activity and network connectivity give rise to non-headache symptoms (premonitory symptoms) that precede pain.

Premonitory symptoms (PSs) are reported by a substantial proportion of individuals with migraine, with prevalence estimates ranging widely across studies, from approximately 29% in population-based to 66% in clinic-based settings, a variability largely dependent on the method of assessment. Although neuroimaging studies have consistently shown hypothalamic activation during the premonitory phase, activation of other areas may also be observed. However, neuroimaging studies have been mostly limited by their reliance on time-based criteria to define the premonitory phase and by insufficient temporal resolution to capture the sequential activation of brain regions within the same phase.

To date, the temporal sequence of events at migraine onset remains unknown and clinical evaluation of symptoms remains the most reliable approach to reconstructing the sequence of events underlying migraine initiation. Recent evidence supports the efficacy of treating the migraine attack during the prodrome. However, the lack of prospective data on the temporal ordering of premonitory symptoms represents a critical gap.

This study will prospectively investigate the temporal sequence of premonitory symptoms across multiple migraine attacks, addressing a critical gap in our understanding of early attack dynamics. By identifying consistent early symptoms and their progression, we aim to define clinically actionable windows for early intervention and provide indirect insight into the sequence of brain network activation underlying migraine onset.

PSs will be collected prospectively. Participants will record premonitory symptoms using a structured electronic diary across a maximum of 5 migraine attacks. They will be instructed to complete the diary at headache onset as early as possible, with timestamped entries to minimise recall bias. Data will be collected using an ad hoc electronic diary developed on the REDCap platform and a standardised case report form (CRF). The diary will collect information on the type, sequence, onset, and duration of PSs experienced before the pain phase.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • premonitory symptoms
  • sequence
  • hypothalamus
  • chronology
  • disability
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Prospective, longitudinal, multicentric study on patients with migraine attending the outpatient clinic of Italian Headache centres who will meet the inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of episodic (EM) or chronic migraine (CM) or CM with medication overuse headache (MOH) according to ICHD-III criteria;
  • Age between 18 and 65 years;
  • At least 2 migraine days (MMD) in the month preceding the inclusion;
  • Migraine history of at least 12 months prior to inclusion
  • Signed written .

Exclusion criteria

Exclusion Criteria:

  • History or current diagnosis of secondary headache disorders as defined by ICHD-III;
  • History of other neurological comorbidities or major psychiatric disorders;
  • History of migraine for \< 12 months prior to the inclusion;
  • Opioid overuse according to the ICHD-III criteria;
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • patients with migraine

    episodic migraine or chronic migraine or migraine with aura

06

What researchers measure

Primary outcomes

  1. Frequency of each symptom as the first premonitory symptom

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. For each premonitory symptom, the percentage of recorded attacks in which it was reported as the first symptom of the premonitory phase. Symptoms are recorded at headache onset for each attack via a structured electronic diary, capturing the type, sequence, onset, and duration of symptoms preceding the pain phase. The denominator is the number of recorded attacks with a premonitory phase.

    Time frame: Up to 6 months

Secondary outcomes

  1. Time from onset of each premonitory symptom to headache onset (categorical intervals)

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. For each premonitory symptom, the time of onset relative to headache onset, classified into predefined intervals: simultaneous with pain onset; less than 1 hour before; 1 to 2 hours before; more than 2 to 6 hours before; more than 6 to 12 hours before. Results are reported as the distribution of attacks across intervals for each symptom (percentage of recorded attacks). Onset times are recorded at headache onset for each attack via a structured electronic diary.

    Time frame: up to 6 months

  2. Time from onset of each premonitory symptom to headache onset (minutes)

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. For each premonitory symptom, the time interval in minutes between its onset and headache onset, recorded for each attack via a structured electronic diary. Results are summarised per symptom (e.g., median minutes before headache onset).

    Time frame: Up to 6 months

  3. Intra-subject consistency of premonitory symptoms across attacks

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. The degree of within-subject agreement in the presence and chronology of premonitory symptoms across multiple attacks of the same participant, recorded via a structured electronic diary. Agreement is summarised per participant and reported across the sample (e.g., concordance in symptom presence and chronology).

    Time frame: Up to 6 months

  4. Evolution and persistence of premonitory symptoms during the headache phase

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. For each premonitory symptom, the evolution and persistence after headache onset, recorded via a structured electronic diary.

    Time frame: Up to 6 months

  5. Patient-level agreement between clinically reported and prospectively recorded presence of premonitory symptoms

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. At the patient level, the agreement between whether participants report experiencing premonitory symptoms during clinical assessment (baseline) and whether they actually record premonitory symptoms during prospectively monitored attacks.

    Time frame: Up to 6 months

  6. Symptom-level concordance between baseline-reported and attack-recorded premonitory symptoms

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. The degree of agreement between premonitory symptoms reported by the participant at baseline and those recorded prospectively at the time of the attack via a structured electronic diary.

    Time frame: Up to 6 months

  7. Premonitory-phase disability and the symptom responsible

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. For each attack, (i) whether the premonitory phase caused a reduction in the participant's usual activities (presence or absence of premonitory-phase disability), and (ii) where disability was present, which premonitory symptom the participant identified as primarily responsible for it.

    Time frame: Up to 6 months

Other outcomes

  1. Patterns of premonitory symptom transition and clustering

    Premonitory symptoms will be recorded at the beginning of each migraine attack for a maximum of 5 migraine attacks per participant. Identification of recurrent patterns in the transition between premonitory symptoms and in their co-occurrence (clustering), across all recorded attacks. Symptom sequences are recorded via a structured electronic diary and analysed using sequence analysis and probabilistic modelling approaches (e.g., transition probabilities between symptoms and identification of symptom clusters).

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
  • Sapienza University of Rome, Polo Pontino, centro cefalee, ICOT
    Latina, Italy 04100, Italy
    Recruiting
08

References and documents

Publications

  • Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, Yu SY, Severt L, Finnegan M, Trugman JM. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023 Dec 16;402(10419):2307-2316. doi: 10.1016/S0140-6736(23)01683-5. Epub 2023 Nov 15. PubMed 37979595 ↗
  • Messina R, Rocca MA, Goadsby PJ, Filippi M. Insights into migraine attacks from neuroimaging. Lancet Neurol. 2023 Sep;22(9):834-846. doi: 10.1016/S1474-4422(23)00152-7. Epub 2023 Jul 18. PubMed 37478888 ↗
  • Karsan N, Goadsby PJ. Neuroimaging in the pre-ictal or premonitory phase of migraine: a narrative review. J Headache Pain. 2023 Aug 11;24(1):106. doi: 10.1186/s10194-023-01617-x. PubMed 37563570 ↗
  • Eigenbrodt AK, Christensen RH, Ashina H, Iljazi A, Christensen CE, Steiner TJ, Lipton RB, Ashina M. Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency. J Headache Pain. 2022 Nov 12;23(1):140. doi: 10.1186/s10194-022-01510-z. PubMed 36371152 ↗
  • Sebastianelli G, Atalar AC, Cetta I, Farham F, Fitzek M, Karatas-Kursun H, Kholodova M, Kukumagi KH, Montisano DA, Onan D, Pantovic A, Skarlet J, Sotnikov D, Caronna E, Pozo-Rosich P; International Headache Academy of the International Headache Society (IHS-iHEAD). Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis. Cephalalgia. 2024 Oct;44(10):3331024241287224. doi: 10.1177/03331024241287224. PubMed 39380339 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 12 months is below that.

Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2026
First posted
Jul 2, 2026
StartActual
Mar 17, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07681466
Collaborators
IRCCS National Neurological Institute "C. Mondino" Foundation, University of Modena and Reggio Emilia, University of Bari, Campus Bio-Medico University, Azienda Ospedaliera Universitaria Mater Domini, Catanzaro, Azienda USL Ferrara, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliero Universitaria Policlinico Modena, Ospedale di Piove di Sacco, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Cliniche Humanitas Gavazzeni, Carlo Besta Neurological Institute, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Responsible party
Gabriele Sebastianelli (Principal investigator, University of Roma La Sapienza) — Principal investigator
First posted
Jul 2, 2026
Start date
Mar 17, 2026
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Gabriele Sebastianelli, MD
Contact
gabriele.sebastianelli@uniroma1.it
+393926337082

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion